Imagine you’re at an arcade trying to win a prize from a game where you have to hit a spinning target. Two players with different strategies are at the game next to you – Player A is trying to hit the target directly, while Player B is trying to knock the target down by hitting it at the base. You notice that Player A seems to be more successful at hitting the target, while Player B is struggling. This analogy can help us understand that when it comes to Alzheimer’s disease and the effectiveness of certain treatments, different ethnic groups may respond differently. Recent research suggests that groundbreaking drugs targeting beta amyloid, a toxic protein linked to Alzheimer’s, may not benefit Black Americans as much as whites because there may be underlying factors driving the disease in Black Americans that are different from those in whites. This highlights the importance of considering diverse populations when developing and testing treatment options for Alzheimer’s. To learn more about this research and its implications, check out the full article.

Groundbreaking treatments for Alzheimer’s disease that work by removing a toxic protein called beta amyloid from the brain may benefit whites more than Black Americans, whose disease may be driven by other factors, leading Alzheimer’s experts told Reuters. The two drugs -…

Read Full Article (External Site)